NCT01184001 is a Phase 1 clinical trial of Treatment A in Rheumatoid Arthritis, sponsored by Pfizer.

Who is sponsoring NCT01184001?

NCT01184001 is sponsored by Pfizer.

What drugs are being tested in NCT01184001?

Interventions in NCT01184001: Treatment A, Treatment B, Treatment B, Treatment A.

What condition does NCT01184001 study?

NCT01184001 studies Rheumatoid Arthritis.

Is NCT01184001 still recruiting?

NCT01184001 is currently completed. Last updated 12 October 2010.

Last reviewed 2010-10-12 · How we verify

NCT01184001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Randomized, 2-Period, 2-Sequence, Open Label, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On Pharmacokinetics Of Tasocitinib (CP-690,550) Tablets In Healthy Subjects

Completed Phase 1 Last updated 12 October 2010

What this trial tests

Phase 1 trial testing Treatment A in Rheumatoid Arthritis in 16 participants. Completed in 1 September 2010.

Timeline

1 September 2010

Primary endpoint
1 September 2010

1 September 2010

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Enrollment	16
Start date	1 September 2010
Primary completion	1 September 2010
Estimated completion	1 September 2010
Sites	1 location across Singapore

Drugs / interventions tested

Treatment A (treatment-a) — full drug profile →
Treatment B (treatment-b) — full drug profile →
Treatment B (treatment-b) — full drug profile →
Treatment A (treatment-a) — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Pfizer — full company profile →

Who can join

Adults 21 to 55, any sex, with Rheumatoid Arthritis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

AUCinf and Cmax of tasocitinib (CP-690,550).
Time frame: PK blood samples out to 24 hours post dose in each of two periods.

Sponsor's own description

In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions. On one occasion the tasocitinib (CP-690,550) tablet will be administered in a fasting condition; On the other occasion the tasocitinib (CP-690,550) tablet will be administered in a fed condition following a standard breakfast meal. The amount of tasocitinib (CP-690,550) in the blood will be measured at various times over 24 hours following each dosing occasion and compared to evaluate for any differences.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tofacitinib.
· 2010 · cited 29× · PMID 21171673 · DOI 10.2165/11588080-000000000-00000

Verify or expand the search:

Other trials of Treatment A

Trials testing the same drug.

NCT07229404 — A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant i · Phase 1 · completed
NCT06661694 — A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults · Phase 1 · withdrawn
NCT06693518 — A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigat · Phase 1 · completed
NCT05868356 — A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib · Phase 1 · completed
NCT07214922 — Relative Bioavailability of Evobrutinib Tablet Batches · Phase 1 · completed

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01184001 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 12 October 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01184001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing